Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Adrian Zwick

Tilman Schlothauer

Jens Fischer

Christian Klein

Stefan Seeber

Joerg Thomas Regula

Georg Fertig

Valeria Lifke

Viktor Levitski

Mario Perro

Pablo Umana

Guy Georges

Pablo Umaña

Sabine Imhof-Jung

Stefan Dengl

Joerg Benz

Ildiko Wuensche

Laura Codarri-Deak

Christian Schantz

Thomas Friess

Claudio Sustmann

Sebastian Fenn

Barbara Weiser

Laura Codarri Deak

Oliver Ploettner

Victor Levitsky

Patrick Alexander Aaron Weber

Ben-Fillippo Krippendorff

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for PD1 and TIM3

The invention provides anti-TPBG antibodies and methods of using the same.

Anti-TPBG antibodies and methods of use

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Growing community of inventors

Penzberg, Germany

Adrian Zwick